Pharma-Brexit is on its way. The announcement of the European Medicine Agency’s move to Amsterdam, various UK government white papers, and comments made by key stakeholders in the UK pharmaceutical industry have led to a wide range of predictions concerning Brexit. While many hope for a Norwegian-type situation where business as usual could continue uninterrupted, others fear that the uncertainty of a “no-deal” outcome has already started a domino effect that could lead to the UK pharmaceutical industry’s collapse. This article argues that something inbetween is most likely and looks at what Brexit could mean in each scenario. It explores why and how both the EU and UK might work through a deal and how these challenges might still provide opportunities for medical writers.